Epic Research Update : Suven Life Science

Suven Life Sciences’ NCE ‘SUVN-3031’ has commenced Phase 1 clinical trial in USA. SUVN-G3031 – a potent, selective, brain penetrant and orally active Histamine H3 antagonist for the treatment of cognitive dysfunction associated with Alzheimer ’s disease / Schizophrenia has completed all the preclinical, safety and early toxicological studies, GLP toxicological studies and was submitted for Investigational New Drug Application (IND) to conduct Phase 1 clinical trial with the indication for Cognition in Alzheimer’s Disease under 505(1) of the Federal Food, Drug and Cosmetic Act (FDCA).



Real Time News & Trading Trends Keep Liking#EpicResearch



Facebook – Twitter – YouTube – Pinterest –Linkedin – Google+



For more information ✆ – 0731-6642300 or Visit http://ift.tt/1k8NnLH

Posted in: Indian Market Tips